Welgene BiotechLtd Past Earnings Performance
Past criteria checks 0/6
Welgene BiotechLtd's earnings have been declining at an average annual rate of -32.9%, while the Life Sciences industry saw earnings growing at 21.5% annually. Revenues have been declining at an average rate of 7.5% per year.
Key information
-32.9%
Earnings growth rate
-35.1%
EPS growth rate
Life Sciences Industry Growth | 5.5% |
Revenue growth rate | -7.5% |
Return on equity | -1.0% |
Net Margin | -0.9% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is Welgene Biotech Co.,Ltd.'s (GTSM:6661) 4.7% Dividend Sustainable?
Mar 19Are Welgene BiotechLtd's (GTSM:6661) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 10Welgene Biotech Co.,Ltd.'s (GTSM:6661) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Jan 13Know This Before Buying Welgene Biotech Co.,Ltd. (GTSM:6661) For Its Dividend
Dec 10Revenue & Expenses BreakdownBeta
How Welgene BiotechLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 281 | -3 | 100 | 24 |
30 Sep 23 | 279 | -2 | 100 | 23 |
30 Jun 23 | 271 | 3 | 95 | 22 |
31 Mar 23 | 299 | 10 | 95 | 21 |
31 Dec 22 | 322 | 10 | 103 | 22 |
30 Sep 22 | 356 | 26 | 108 | 23 |
30 Jun 22 | 366 | 21 | 111 | 23 |
31 Mar 22 | 336 | 14 | 106 | 22 |
31 Dec 21 | 313 | 14 | 97 | 22 |
30 Sep 21 | 312 | 9 | 98 | 21 |
30 Jun 21 | 329 | 19 | 99 | 21 |
31 Mar 21 | 355 | 22 | 102 | 21 |
31 Dec 20 | 398 | 30 | 105 | 22 |
30 Sep 20 | 423 | 33 | 110 | 24 |
30 Jun 20 | 451 | 34 | 114 | 23 |
31 Mar 20 | 429 | 29 | 115 | 23 |
31 Dec 19 | 417 | 31 | 115 | 21 |
30 Sep 19 | 392 | 31 | 112 | 18 |
30 Jun 19 | 370 | 34 | 114 | 16 |
31 Mar 19 | 377 | 31 | 119 | 16 |
31 Dec 18 | 384 | 28 | 123 | 16 |
30 Sep 18 | 366 | 23 | 119 | 16 |
30 Jun 18 | 348 | 17 | 115 | 17 |
31 Mar 18 | 337 | 20 | 108 | 16 |
31 Dec 17 | 326 | 24 | 101 | 16 |
30 Sep 17 | 312 | 20 | 98 | 15 |
30 Jun 17 | 298 | 17 | 96 | 15 |
31 Mar 17 | 288 | 10 | 98 | 15 |
31 Dec 16 | 278 | 4 | 100 | 14 |
31 Dec 15 | 277 | 21 | 108 | 12 |
31 Dec 14 | 270 | 21 | 128 | 10 |
Quality Earnings: 6661 is currently unprofitable.
Growing Profit Margin: 6661 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6661 is unprofitable, and losses have increased over the past 5 years at a rate of 32.9% per year.
Accelerating Growth: Unable to compare 6661's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6661 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (0.6%).
Return on Equity
High ROE: 6661 has a negative Return on Equity (-1.05%), as it is currently unprofitable.